News

Our Healthcare News

Revance's RT002 Demonstrates Unprecedented Efficacy and Duration in Largest-Ever Aesthetic Neuromodulator Clinical Program

NEWARK, California—(BUSINESS WIRE)—Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology company developing next-generation neuromodulators for use in treating aesthetic and therapeutic conditions, today announced its long-acting neuromodulator…  

Dec 04 2018

Revance Announces China Market License Agreement with Fosun Pharma for RT002

NEWARK, Califronia.—(BUSINESS WIRE)—Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology company developing next-generation neuromodulators for use in treating aesthetic and therapeutic conditions, today announced that the company…  

Dec 04 2018

Abicipar Phase 3 Data Presented at AAO Conference in Chicago: Potential to Be the First Fixed 12-Week Anti-VEGF Therapeutic

Zurich-Schlieren, SWITZERLAND—Molecular Partners AG (SIX: MOLN), a clinical-stage biopharmaceutical company pioneering the use of DARPin® therapeutics* to treat serious diseases, today announced that the phase…  

Oct 29 2018

Molecular Partners and AstraZeneca Announce Collaboration on Molecular Partners' Ongoing Oncology Clinical Study with MP0250 in EGFR-Mutated NSCLC

ZURICH-SCHLIEREN, Switzerland—Molecular Partners AG (SIX: MOLN), a clinical-stage biopharmaceutical company developing a new class of drugs known as DARPin® therapies*, announced today that Molecular Partners…  

Apr 11 2018

Thermo Fisher Scientific Acquires IntegenX, Leading Provider of Rapid DNA Technology for Human Identification

CARLSBAD, California—Thermo Fisher Scientific Inc., the world leader in serving science, today announced that it has acquired IntegenX Inc., which provides a rapid DNA platform…  

Mar 16 2018

Molecular Partners' Collaboration Partner Allergan Exercises Options for Two DARPin Product Candidates in Ophthalmology

ZURICH-SCHLIEREN, Switzerland—Molecular Partners AG (ticker: MOLN), a clinical-stage biopharmaceutical company developing a new class of drugs known as DARPin® therapies*, today announced that Allergan has…  

Jan 03 2018

Stryker Announces Definitive Agreement to Acquire Entellus

KALAMAZOO, Michigan – – Stryker Corporation (NYSE: SYK) announced today a definitive merger agreement to acquire Entellus Medical, Inc. (NASDAQ: ENTL) for $24.00 per share,…  

Dec 07 2017

Revance’s RT002 Meets Primary and Secondary Endpoints, Achieves 6-Month Duration in Phase 3 Trials

NEWARK, Calif.—(BUSINESS WIRE)—Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology company developing neuromodulators for use in treating aesthetic and underserved therapeutic conditions, today announced its next-generation neuromodulator…  

Dec 05 2017

Otsuka and Proteus Announce First U.S. FDA Approval of a Digital Medicine System:  ABILIFY MYCITE

TOKY, Japan and REDWOOD CITY, California– Otsuka Pharmaceutical Co., Ltd.  (Otsuka) and Proteus Digital Health (Proteus) today announce that the United States Food and Drug…  

Nov 14 2017